News & Interviews
Gene and Cell Therapies – A Major Investment Focus in 2020
2020 will soon be a record year for biotechnology. In the first half of 2020, the biotechnology industry obtained $16.55 billion in investment. Cell and
Insider Highlights from Bioinsider’s Friday Roundtable, “Drug Shortage Challenges in the Time of COVID-19”
Insider Highlights from Bioinsider’s Friday Roundtable, “Drug Shortage Challenges in the Time of COVID-19” The COVID-19 pandemic has severely impacted the global drug supply chain,
Clinical Trials During and After Covid-19
Current clinical trials were already stressed to function in a timely manner prior to Covid-19. Perpetual supply chain disruptions, in-person discontinuances, and constantly changing regulatory
4 Benefits of Virtual Meetings
Here are four benefits that virtual meetings have over in-person conferences. As the Covid-19-induced new norm is underway, communication is rapidly and universally approaching to
Highlights from Bioinsider’s Therapeutic Pipeline for COVID-19 Virtual Meeting
On September 17, scientists from academia and biotech in different locations were brought together in a virtual forum to learn about the latest preclinical and
How to evolve a monoclonal antibody response to SARS-CoV-2
Dr. Crowe is a viral immunologist and board-certified pediatric infectious diseases specialist at Vanderbilt University Medical Center. A handful of vaccine candidates and monoclonal antibodies
Potent neutralizing antibodies to combat SARS today and tomorrow
Adagio Therapeutics believes broadly neutralizing antibodies will offer best-in-class potency and coverage against SARS-CoV-2 and protection against future coronavirus outbreaks. Dr. Laura Walker, Adagio’s CSO, discusses
Insider Highlights from Bioinsider’s Friday Roundtable, “Challenges of Conducting Bioanalysis in Clinical Trials in the Midst of COVID-19 Pandemic”
The COVID-19 pandemic has negatively impacted all facets of clinical trials including patients, sponsors, regulatory agencies, and central labs. Bioinsider recently hosted its virtual Friday
Insider Highlights from Bioinsider’s Friday Roundtable, “How COVID-19 has Changed the Immunogenicity Risk of Immune Modulatory Biologics”
Insider Highlights from Bioinsider’s Friday Roundtable, “How COVID-19 has Changed the Immunogenicity Risk of Immune Modulatory Biologics” Scientists are making rapid and significant strides to
Alpha-Ketoamide Inhibitors of the SARS-CoV-2 Main Protease
Rolf Hilgenfeld, PhD, Professor, Institute of Molecular Medicine, University of Luebeck, Germany At the forefront of battling coronaviruses since 1998, Dr. Rolf Hilgenfeld is focused
Neutrophil-Targeting Peptides as a Treatment for COVID-19
PEEL Therapeutics is introducing a natural peptide that evolved in newborns to block inflammation as a new therapeutic approach to help with the current COVID-19
